Diabetes
-
Permission granted by Dexcom
Dexcom chief commercial officer to retire
Teri Lawver is leaving the diabetes tech company during a challenging time, with sales slowing after a workforce restructuring.
By Elise Reuter • Oct. 25, 2024 -
Courtesy of Boston Scientific
Boston Scientific, Edwards and Dexcom usher in second week of earnings
Johnson & Johnson, Abbott and Intuitive Surgical made a mixed start to earnings season last week.
By Nick Paul Taylor • Oct. 22, 2024 -
Courtesy of Cue Health Press Kit
FDA labels Cue’s recall of COVID tests as Class II, revokes EUAs
Cue Health began the recall of nearly 250,000 COVID-19 test kits in May, shortly after the FDA advised people at home and healthcare professionals not to use the products.
By Nick Paul Taylor • Oct. 17, 2024 -
Permission granted by Abbott
Abbott CEO sees ‘mass market potential’ for CGMs
Robert Ford’s comments come as new CGMs and insulin pumps continue to roll out in the diabetes tech space, including over-the-counter glucose sensors.
By Ricky Zipp • Oct. 16, 2024 -
Mario Tama via Getty Images
J&J, Abbott and Intuitive kick off latest medtech earnings season
From pulsed field ablation to diabetes tech and surgical robots, the updates will provide an early look at how key medtech markets performed last quarter.
By Nick Paul Taylor • Oct. 14, 2024 -
Courtesy of Medtronic
Medtronic recalls Minimed insulin pumps for reduced battery life
The company said it received 170 reports of hyperglycemia and 11 reports of diabetic ketoacidosis in the U.S. that could be linked to the problem.
By Susan Kelly • Oct. 7, 2024 -
halbergman via Getty Images
Top medtech conferences in 2025
The lineup includes industrywide conferences and events covering the latest medtech trends in diabetes, orthopedics, cardiac care and surgical robotics.
By Ricky Zipp • Oct. 1, 2024 -
Permission granted by Abbott Laboratories
Abbott ramps up Libre 3 production amid shortages
Some people are facing delays in filling prescriptions for the glucose sensor. Abbott expects to resolve the problem soon.
By Elise Reuter • Sept. 20, 2024 -
Permission granted by Senseonics
Senseonics receives FDA clearance for one-year CGM
Commercial partner Ascensia is in discussions with insulin pump manufacturers to create an automated insulin delivery system.
By Elise Reuter • Sept. 17, 2024 -
Permission granted by Roche
Roche to launch new CGM in Europe in ‘coming weeks’
Roche will roll out its Accu-Chek Smartguide in the Netherlands, Switzerland and Germany. The company hopes to stand out from competitors with features to predict hypoglycemia.
By Elise Reuter • Sept. 12, 2024 -
Permission granted by Abbott
Dexcom, Abbott OTC glucose sensors add to busy year for diabetes tech
New over-the-counter sensors, an Abbott-Medtronic partnership and Roche’s first CGM are among diabetes technology’s top stories so far in 2024. Check out MedTech Dive’s roundup of the latest news.
By Ricky Zipp • Sept. 11, 2024 -
Courtesy of Abbott
Abbott debuts Lingo over-the-counter CGM in the US
Priced at $49 for one 14-day sensor, or $89 per month, Abbott’s offering is competitive with Dexcom’s Stelo sensor.
By Elise Reuter • Sept. 6, 2024 -
Permission granted by Abbott Laboratories
Abbott partners with maker of ‘bionic pancreas’
Abbott will integrate its latest glucose sensor with Beta Bionics’ automated insulin delivery system.
By Nick Paul Taylor • Sept. 5, 2024 -
Permission granted by Nasdaq
Embecta gets FDA nod for insulin patch pump
Embecta’s first patch pump features a larger insulin reservoir, based on feedback from people with Type 2 diabetes.
By Elise Reuter • Sept. 3, 2024 -
Permission granted by Insulet
Q&AInsulet’s Trang Ly on overcoming ‘clinical inertia’ in diabetes care
Automated insulin delivery for Type 2 patients can help change minds among physicians who have been reluctant to prescribe pump therapy, the chief medical officer said in an interview.
By Susan Kelly • Aug. 27, 2024 -
Courtesy of Insulet
Insulet expands Omnipod 5 pump to people with Type 2 diabetes
The FDA clearance marks the first automated insulin delivery system for people with Type 2 diabetes.
By Elise Reuter • Aug. 26, 2024 -
Courtesy of Dexcom
Dexcom prices first over-the-counter glucose monitor
Known as Stelo, the device is intended for people who don’t take insulin and costs $89 per month.
By Elise Reuter • Aug. 26, 2024 -
Courtesy of Tandem Diabetes Care
Tandem warns iPhone app still draining insulin pump batteries
Despite a software update in March, users are still reporting that the app is rapidly depleting their insulin pump batteries, causing unexpected shutdowns.
By Elise Reuter • Aug. 15, 2024 -
Permission granted by Medtronic
Abbott, Medtronic partner on diabetes tech
Abbott will develop a glucose sensor that can only connect with Medtronic's insulin delivery technology.
By Elise Reuter • Aug. 7, 2024 -
Courtesy of Ascensia Diabetes Care
Q&AAscensia’s new head of CGM talks plans for a 365-day sensor
Brian Hansen recently joined Ascensia, which markets Senseonics’ implantable glucose sensors. The current version lasts 180 days, but Senseonics is seeking FDA approval for a one-year sensor.
By Elise Reuter • Aug. 6, 2024 -
Joe Raedle via Getty Images
Patient shares a day in the life with diabetes at FDA’s first Home Health Hub meeting
The initiative, led by new CDRH Acting Director Michelle Tarver, is intended to improve health equity by including people’s living conditions in device design.
By Elise Reuter • July 30, 2024 -
Courtesy of Tandem Diabetes Care
Q&ATandem CMO shares Mobi feedback, expansion plans
MedTech Dive caught up with Chief Medical Officer Jordan Pinsker to talk about early feedback on Tandem’s smallest insulin pump and what’s next for the device.
By Elise Reuter • July 29, 2024 -
Permission granted by Dexcom
Dexcom shares plunge on lower sales outlook
“I’m just kind of in shock,” an analyst said on the earnings call, asking for more detail on the forecast cut.
By Elise Reuter • July 26, 2024 -
Permission granted by Abbott Laboratories
Abbott recalls Freestyle Libre 3 sensors due to incorrect glucose readings
A spokesperson for Abbott said the recall “may impact less than 1% of Libre 3 users in the U.S.”
By Nick Paul Taylor • July 26, 2024 -
Permission granted by Nasdaq
Diabetes device firm Embecta considers sale: Financial Times
Two years after Embecta spun out of BD, the firm is now exploring a potential sale, the Financial Times reported.
By Elise Reuter • July 22, 2024
